ChemoCentryx has initiated a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).

Developed by ChemoCentryx under the alliance with GlaxoSmithKline (GSK), CCX168 specifically targets the C5a receptor (C5aR), a potent pro-inflammatory mediator responsible for AAV, as well as several other autoimmune diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised double-blind placebo-controlled trial will evaluate the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis, while assessing the potential for reducing or eliminating the use of corticosteroids in the patients.

ChemoCentryx president and CEO Thomas Schall said the company’s drug candidate have shown the promise of blocking specific chemokines and chemoattractant cytokines in the treatment of autoimmune and inflammatory diseases.